Last Update Time:
21-Mar-2025 09:46:15
ISIN:
INE700A01033
Sector:
Healthcare
Symbol:
JUBLPHARMA
Jubilant Pharmova Limited
₹917.50
₹18.55
(2.06%)
▲
Prev. Close
₹898.95
Open
₹900.00
Close
₹0.00
Range
₹871.63 - ₹963.38
High
₹919.00
Low
₹900.00
Ind. Close
₹0.00
VWAP
₹909.78
The current stock price of Jubilant Pharmova Limited is ₹917.50, with a target price range between ₹871.63 and ₹963.38. The stock has experienced a price change of ₹18.55 (2.06%), reflecting recent market volatility.
Today's opening price was ₹900.00, while the previous close stood at ₹898.95.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Jubilant Pharmova Limited Price Chart
Jubilant Pharmova Limited Pre Open Market Overview: 21-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 900
- Previous Close Price: 898.95
- Change: 1.05%
- Total Traded Volume: 382
- Total Buy Quantity: 1,872
- Total Sell Quantity: 2,941
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 892.20 | 5.00 | 0.00 |
| 895.00 | 130.00 | 0.00 |
| 899.00 | 6.00 | 0.00 |
| 900.00 | 61.00 | 0.00 |
| 900.10 | 329.00 | 0.00 |
| 900.40 | 0.00 | 14.00 |
| 902.35 | 0.00 | 14.00 |
| 904.30 | 0.00 | 14.00 |
| 906.25 | 0.00 | 14.00 |
| 907.45 | 0.00 | 17.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 917.60 | 3 | 918.30 | 93 |
| 917.55 | 1 | 918.70 | 32 |
| 917.50 | 5 | 918.90 | 8 |
| 917.45 | 1 | 918.95 | 26 |
| 917.40 | 3 | 919.00 | 261 |
Total Buy Quantity: 1872
Total Sell Quantity: 2941
Shareholding Patterns of Jubilant Pharmova Limited
Key Trade Statistics of Jubilant Pharmova Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.17 |
| Traded Value (₹ Cr.) | 1.53 |
| Total Market Cap (₹ Cr.) | 14,614.04 |
| Free Float Market Cap (₹ Cr.) | 6,950.86 |
| Impact cost | 0.07 |
| Quantity Traded | 202,510.00 |
| Deliverable Quantity | 61,702.00 |
| % of Quantity to Traded | 30.47 |
| Security VaR | 18.12 |
| Index VaR | N/A |
| VaR Margin | 18.12 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 21.62 |
| Face Value | 1 |
Key Price Statistics of Jubilant Pharmova Limited
The 52-week high for Jubilant Pharmova Limited was ₹1,309.90, recorded on 07-Nov-2024. On the other hand, the 52-week low stands at ₹558.75, with the lowest value recorded on 20-Mar-2024.
The upper band for trading is ₹1,078.70, and the lower band is ₹719.20. The price band is 20%.
The stock's daily volatility stands at 2.78, while the annualized volatility is 53.11. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (07-Nov-2024) | 1,309.90 |
| 52 Week Low (20-Mar-2024) | 558.75 |
| Upper Band | 1,078.70 |
| Lower Band | 719.20 |
| Price Band (%) | 20 |
| Daily Volatility | 2.78 |
| Annualised Volatility | 53.11 |
| Tick Size | 0.05 |
Key Securities Statistics of Jubilant Pharmova Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 16-Jun-2003 |
| Adjusted P/E | 18.89 |
| Symbol P/E | 23.09 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Jubilant Pharmova Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Jubilant Pharmova Limited
| Subject | Date |
|---|---|
| General Updates | 20-Mar-2025 |
| General Updates | 12-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 04-Mar-2025 |
| Rumour Verification - Regulation 30(11) | 25-Feb-2025 |
| General Updates | 24-Feb-2025 |
| Investor Presentation | 24-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 05-Feb-2025 |
| Copy of Newspaper Publication | 01-Feb-2025 |
Corporate Actions of Jubilant Pharmova Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Dividend - Rs 5 Per Share | 02-Aug-2024 |
| 1 | Dividend - Rs 5 Per Share | 10-Aug-2023 |
| 1 | Dividend - Rs 5 Per Share | 11-Aug-2022 |
| 1 | Dividend - Rs 5 Per Share | 05-Aug-2021 |
| 1 | Demerger | 04-Feb-2021 |
| 1 | Interim Dividend - Rs 5 Per Share | 09-Mar-2020 |
| 1 | Annual General Meeting/Dividend - Rs 4.50 Per Share | 12-Sep-2019 |
| 1 | Annual General Meeting/Dividend Rs 3 Per Share | 12-Sep-2018 |
| 1 | Annual General Meeting/ Dividend - Rs 3/- Per Share | 16-Aug-2017 |
| 1 | Annual General Meeting/ Dividend - Rs 3/- Per Share | 18-Aug-2016 |
| 1 | Annual General Meeting/ Dividend - Rs 3/- Per Share | 20-Aug-2015 |
| 1 | Annual General Meeting / Dividend - Rs 3/- Per Share | 21-Aug-2014 |
| 1 | Annual General Meeting And Dividend Rs.3/- Per Share | 14-Aug-2013 |
| 1 | Annual General Meeting/ Dividend Rs 3 Per Share | 14-Aug-2012 |
| 1 | Annual General Meeting And Dividend Rs.2/- Per Share | 10-Aug-2011 |
| 1 | Scheme Of Demerger | 25-Nov-2010 |
| 1 | Annual General Meeting And Dividend Rs.2/- Per Share | 17-Sep-2010 |
| 1 | Dividend-Rs.1.50 Pr Share | 29-Jun-2009 |
| 1 | Agm/Div-Rs.1.50 Per Share | 17-Sep-2008 |
| 1 | Agm/Div-Rs.1.25/- Per Sh | 17-Sep-2007 |
Board Meetings of Jubilant Pharmova Limited
Financial Results of Jubilant Pharmova Limited
Company Directory of Jubilant Pharmova Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.jubl.com | Head Office/ Corporate Office | Plot 1A, Sector 16A, Noida | N/A |
| www.jubl.com | Registered Office | Bhartia Gram, Gajraula, District Amroha | N/A |
| www.jubl.com | Transfer Agent | Alankit Assignment Limited Alankit House, 2E/21, Jhandewalan Extn. | NEW DELHI |
Insider Trading of Jubilant Pharmova Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Jubilant Employees Welfare Trust | 43786664 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 4319823 | Sell |
| 7(2) | Jubilant Employees Welfare Trust | 12177179 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 8190507 | Sell |
| 7(2) | Jubilant Employees Welfare Trust | 16920797 | Sell |
| 7(2) | Jubilant Employees Welfare Trust | 35895842 | Sell |
| 7(2) | JUBILANT EMPLOYEES WELFARE TRUST | 1422655 | Sell |
| 7(2) | Jubilant Employees Welfare Trust | 19725311 | Sell |
| 7(2) | Jubilant Employees Welfare Trust | 13380424 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 5688793 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 6300392 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 34314730 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 38607125 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 8544211 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 37657961 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 8806262 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 23109648 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 2682259 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 16696192 | Buy |
| 7(2) | Jubilant Employees Welfare Trust | 1581289 | Buy |
Annual Reports of Jubilant Pharmova Limited
Investor Complaints of Jubilant Pharmova Limited
Event Calendar of Jubilant Pharmova Limited
| Purpose | Details |
|---|---|
| Results/Dividend | To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2010. (2) Recommendation of Dividend for the year ended March 31, 2010. |
| Results/Dividend | To inter-alia consider : (1) Audited Financial Results of the Company for the year ended March 31, 2011; (2) Recommendation of Dividend for the Year ended March 31, 2011. |
| Results/Dividend | To inter-alia consider : (1) Audited Financial Results of the Company for the year ended March 31, 2012; (2) Recommendation of Dividend for the Year ended March 31, 2012. |
| Results/Dividend | To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2013; (2) Recommendation of Dividend for the Year ended March 31, 2013. |
| Results | to inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013. |
| Results | to inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013 |
| Results | To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2013. |
| Results/Dividend | To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2014; (2) Recommendation of Dividend for the Year ended March 31, 2014. Further as per the Company's insider Trading Code, the trading window for dealing in the securities of the Company would remain closed for all Directors/Officers/ Designated Employees of the Company from May 19, 2014 to May 27, 2014 (both days inclusive). |
| Results | To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2014. |
| Results | To inter-alia, consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014. |
| Results | to inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2014. |
| Results/Dividend | To inter-alia consider: 1. Audited Financial Results of the Company for the year ended March 31, 2015. 2. Recommendation of Dividend for the year ended March 31, 2015. |
| Results | To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2015. |
| Results | To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2015. |
| Results | to inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2015. |
| Results/Dividend | To inter-alia consider:1. Audited Financial Results of the Company for the year ended March 31, 2016;2. Recommendation of Dividend for the year ended March 31, 2016. |
| Results | To inter-alia consider Unaudited Financial Results of the Company for the quarter ended June 30, 2016.Further, as per the Company s Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company would remain closed for the Designated Persons of the Company from August 2, 2016 to August 11, 2016 (both days inclusive) |
| Results | to inter-alia consider Unaudited Financial Results of the Company for the quarter ended September 30, 2016. |
| Others | Inter-alia consider the proposal to issue Non-Convertible Debentures up to an amount of Rs.1,000 crore. |
| Results | To inter-alia consider Unaudited Financial Results of the Company for the quarter ended December 31, 2016. |
| Results/Dividend | To inter alia consider: 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2017. 2. Recommendation of Dividend for the Financial Year ended March 31, 2017. |
| Results | inter alia, to consider and approve the Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Results | To inter alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2017. |
| Results | To inter alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended September 30, 2017. |
| Results | To inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Fund Raising | Proposal to consider issue of Non-Convertible Debentures |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ￂﾑListing Regulationsￂﾒ), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, February 1, 2019, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2018.This is for information and record. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations ), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, January 31, 2020, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2019.This is for information and record. |
| Dividend | To consider interim dividend for FY 2019-20 |
| Financial Results/Fund Raising | In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 29, 2020, to inter-alia consider:ￂﾠ1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2020.ￂﾠ2. Issue of Non-Convertible Debentures upto Rs. 100 Crore.This is for information and record. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020.In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations ), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, September 4, 2020, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2020.This is for information and record. |
| Financial Results/Fund Raising | To consider and approve the financial results for the quarter and half year ended September 30, 2020 and Issue of Non-Convertible Debentures |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Jubilant Pharmova Limited has informed the Exchange about Board Meeting to be held on 02-Aug-2022 to consider financial results for the period ended June 2022 |
| Financial results | Jubilant Pharmova Limited has informed the Exchange about Board Meeting to be held on 21-Oct-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Other business matters | To consider and approve the financial results for the period ending June 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Jubilant Pharmova Limited
| Company | Period | Reg.7 | Reg.40 |
|---|---|---|---|
| Jubilant Pharmova Limited | 31-MAR-2024 | ||
| Jubilant Pharmova Limited | 31-MAR-2023 | ||
| Jubilant Pharmova Limited | 31-MAR-2022 | ||
| Jubilant Pharmova Limited | 31-MAR-2021 |
Voting Results of Jubilant Pharmova Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 30-AUG-2024 | AGM | To receive, consider and adopt:n(a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2024 together with the Reports of the Board of Directors and the Auditors thereon; andn(b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2024 together with the Report of the Auditors thereon. n |
| 30-AUG-2024 | AGM | 4. To appoint a Director in place of Mr. Arjun Shankar Bhartia [DIN: 03019690], who retires by rotation and, being eligible, offers himself for re-appointment. |
| 30-AUG-2024 | AGM | 3. To appoint a Director in place of Mr. Arvind Chokhany [DIN: 06668147], who retires by rotation and, being eligible, offers himself for re-appointment. |
| 30-AUG-2024 | AGM | To declare a Dividend of ￂ 5 per equity share of the face value of ￂ1 each for the Financial Year ended March 31, 2024 |
| 23-AUG-2024 | Postal Ballot | Appointment of Dr. Ramakrishnan Arul (DIN: 08236356) as Director of the Company |
| 23-AUG-2024 | Postal Ballot | Approval for grant of employee stock options and/or restricted stock units to the employees of the subsidiary companies of the company under the amended and restated Jubilant Pharmova Employees Stock Option Plan 2018. |
| 23-AUG-2024 | Postal Ballot | Approval for amendment of Jubilant Pharmova Employees Stock Option Plan 2018 and adoption of an amended and restated Employees Stock Option Plan 2018 |
| 23-AUG-2024 | Postal Ballot | Appointment of Dr. Ramakrishnan Arul (DIN: 08236356) as a Whole-time Director of the Company |
| 26-JUN-2024 | Postal Ballot | Re-appointment of Mr. Arvind Chokhany (DIN:06668147) as a Whole-time Director (designated as Group Chief Financial Officer and Whole-time Director) of the Company |
| 26-JUN-2024 | Postal Ballot | Appointment of Ms. Shivpriya Nanda (DIN: 01313356)nas an Independent Director of the Companyn |
| 26-JUN-2024 | Postal Ballot | Appointment of Dr. Harsh Mahajan (DIN: 00824227)nas an Independent Director of the Companyn |
| 25-JAN-2024 | Postal Ballot | Appointment of Mr. Jinang Pratap Parekh (DIN:10366075) as Director of the Company - Ordinary Resolution |
| 25-JAN-2024 | Postal Ballot | Appointment of Mr. Jinang Pratap Parekh [DIN:10366075] as a Whole-time Director of the Company ￂ - Special Resolution |
| 31-AUG-2023 | AGM | a) Adoption of the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon andn b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2023 together with the Report of the Auditors thereon. |
| 31-AUG-2023 | AGM | Re-appointment of Mr. Arun Seth (DIN: 00204434) as an Independent Director of the Company |
| 31-AUG-2023 | AGM | Appointment of M/s. Walker Chandiok & Co LLP, Chartered Accountants (ICAI Registration No.: 001076N/ N500013) as Statutory Auditors of the Company |
| 31-AUG-2023 | AGM | Appointment of Director in place of Mr. Hari S. Bhartia [DIN: 00010499], who retires by rotation and, being eligible, offers himself for re-appointment. |
| 31-AUG-2023 | AGM | Appointment of Director in place of Mr. Shyam S. Bhartia [DIN: 00010484], who retires by rotation and being eligible, offers himself for re-appointment. |
| 31-AUG-2023 | AGM | Declaration of dividend for the year ended March 31, 2023. |
| 21-AUG-2023 | Postal Ballot | Appointment of Mr. Priyavrat Bhartia (DIN 00020603) as Managing Director |
FAQs on Jubilant Pharmova Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.